Stocks of Pliant Therapeutics Inc. (NASDAQ:PLRX) traded higher last session on Wall Street, down -0.80% to $23.44.
According to the data, Pliant Therapeutics Inc. (NASDAQ:PLRX) has 11 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $53.00 and a low of $33.00, we find $41.00. Given the previous closing price of $23.63, this indicates a potential upside of 73.51 percent. PLRX stock price is now 18.66% away from the 50-day moving average and 50.29% away from the 200-day moving average. The market capitalization of the company currently stands at $1.15B.
A total of 0 analysts have issued a hold rating and 11 have given it a buy rating. Brokers who have rated the stock have averaged $42.10 as their price target over the next twelve months.
With the price target of $33, Stifel recently initiated with Buy rating for Pliant Therapeutics Inc. (NASDAQ: PLRX). On December 07, 2022, JP Morgan recently initiated its ‘Overweight’ rating on the stock quoting a target price of $42, while ‘Citigroup’ rates the stock as ‘Buy’.
In other news, Coulie Bernard, President and CEO sold 5,000 shares of the company’s stock on Jan 09. The stock was sold for $95,829 at an average price of $19.17. Upon completion of the transaction, the President and CEO now directly owns 93,812 shares in the company, valued at $2.2 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 06, President and CEO Coulie Bernard sold 15,000 shares of the business’s stock. A total of $285,584 was realized by selling the stock at an average price of $19.04. This leaves the insider owning 93,812 shares of the company worth $2.2 million. Insiders disposed of 4,050,928 shares of company stock worth roughly $94.95 million over the past 1 year. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PLRX stock. A new stake in Pliant Therapeutics Inc. shares was purchased by AVIDITY PARTNERS MANAGEMENT LP during the first quarter worth $46,437,000. JENNISON ASSOCIATES LLC invested $40,809,000 in shares of PLRX during the first quarter. In the first quarter, DEEP TRACK CAPITAL, LP acquired a new stake in Pliant Therapeutics Inc. valued at approximately $32,810,000. PRICE T ROWE ASSOCIATES INC /MD/ acquired a new stake in PLRX for approximately $28,874,000. POLAR CAPITAL HOLDINGS PLC purchased a new stake in PLRX valued at around $25,784,000 in the second quarter. In total, there are 139 active investors with 94.20% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $23.59 for Pliant Therapeutics Inc. (NASDAQ: PLRX). During the past 12 months, Pliant Therapeutics Inc. has had a low of $3.96 and a high of $26.25. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 14.00, and a quick ratio of 14.00. The fifty day moving average price for PLRX is $19.72 and a two-hundred day moving average price translates $15.67 for the stock.
The latest earnings results from Pliant Therapeutics Inc. (NASDAQ: PLRX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.82, missing analysts’ expectations of -$0.81 by -0.01. This compares to -$0.75 EPS in the same period last year. The company reported revenue of $1.48 million for the quarter, compared to $1.61 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -7.95 percent. For the current quarter, analysts expect PLRX to generate $1.59M in revenue.
Pliant Therapeutics Inc.(PLRX) Company Profile
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.